Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron).

Abstract

Ethinylestradiol sulfonate (Turisteron) is an orally highly active depot-estrogen with relatively low side effects. In men with prostatic cancer, weekly administration of 2 mg Turisteron resulted in a striking decrease of the biologically active free testosterone level to less than 2% of the basal level; i.e., even significantly lower than after orchidectomy. Turisteron was able to normalize the 5 year survival rate in men with advanced non-metastatic cancer (T3NxM0) and to increase the survival rate significantly in men with metastatic cancer (T3-4, Nx, M1). Hence, due to our experience, Turisteron treatment is a very effective, non-expensive and well tolerated therapy for prostatic cancer.

• Authors: G Dörner, D Schnorr, F Stahl, W Rohde
• Journal: Experimental and clinical endocrinology (Exp Clin Endocrinol) Vol. 86 Issue 2 Pg. 190-6 (Dec 1985) ISSN: 0232-7384 [Print] Germany
• PMID: 3912197 (Publication Type: Journal Article)

Chemical References

• Delayed-Action Preparations
• ethinyl estradiol sulfonate
• Gonadotropin-Releasing Hormone
• Testosterone
• Ethinyl Estradiol

Topics

• Aged
• Delayed-Action Preparations
• Ethinyl Estradiol (adverse effects, analogs & derivatives, therapeutic use)
• Gonadotropin-Releasing Hormone (therapeutic use)
• Humans
• Male
• Middle Aged
• Orchiectomy
• Prostatic Neoplasms (drug therapy)
• Testosterone (blood)